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ABSTRACT
In this issue of ckj, Tabibzadeh et al. report one of the largest series of patients with MYH9 mutations and kidney disease.
The cardinal manifestation of MYH9-related disease is thrombocytopenia with giant platelets. The population frequency of
pathogenic MYH9 mutations may be at least 1 in 20 000. The literature abounds in misdiagnosed cases treated for idiopathic
thrombocytopenic purpura with immune suppressants and even splenectomy. Additional manifestations include
neurosensorial deafness and proteinuric and hematuric progressive kidney disease (at some point, it was called Alport
syndrome with macrothrombocytopenia), leucocyte inclusions, cataracts and liver enzyme abnormalities, resulting in
different names for different manifestation combinations (MATINS, May–Hegglin anomaly, Fechtner, Epstein and Sebastian
syndromes, and deafness AD 17). The penetrance and severity of kidney disease are very variable, which may obscure the
autosomal dominant inheritance. A correct diagnosis will both preclude unnecessary and potentially dangerous
therapeutic interventions and allow genetic counselling and adequate treatment. Morphological erythrocyte, granulocyte
and platelet abnormalities may allow the future development of high-throughput screening techniques adapted to clinical
peripheral blood flow cytometers.
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INTRODUCTION
In this issue of ckj, Tabibzadeh et al. report one of the largest se-
ries of patients with MYH9 mutations and kidney disease [1].
This offers the opportunity to emphasize some key concepts to
lower the suspicion threshold and improve outcomes, comple-
menting excellent recent reviews [2–4].
WHAT IS MYH9-RELATED DISEASE?
MYH9-related disease (MYH9-RD) refers to clinical manifesta-
tions dependent on MYH9 genetic variants. Before the
description of the underlying genetic cause in 2000, different
syndromes had been described encompassing combinations of
potential disease manifestations [5, 6] (Figure 1). OMIM terms
the condition MATINS (MAcroThrombocytopenia and granulo-
cyte Inclusions with or without Nephropathy or Sensorineural
hearing loss), emphasizing the nearly constant presence of low
numbers of large platelets with variable penetrance of other
manifestations [7]. Certain genetic variants (e.g. R705H) are as-
sociated mainly with neurosensorial deafness caused by cochle-
osaccular degeneration [2]. The combination of nephropathy
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and sensorineural hearing loss led to the term ‘Alport syndrome
with macrothrombocytopenia’, no longer in use, as Alport syn-
drome is caused by mutations in COL4A3, COL4A4 or COL4A5
genes.
HOW FREQUENT IS MYH9-RD?
The frequency of MYH9-RD is unknown. In the EXAC database,
six loss-of-function genetic variants (stop codon, frameshift or
splice acceptor/donor) were present in around 120 000 alleles,
for an allele frequency of around 1 in 20 000 [8]. This is very sim-
ilar to the estimated frequency in the Greifswald region of
Germany; five unrelated families in a population of around
250 000 habitants [9]. If we estimate at least two affected mem-
bers per family, this yields a frequency of around 1 in 25 000.
Since the disease is underdiagnosed and missense variants may
also result in disease, we conclude that the frequency of MYH9-
RD is at least 1 in 20 000–25 000. The rate of de novo mutations is
relatively high at >30% [3].
HOW IS MYH9-RD INHERITED?
MYH9-RD is autosomal dominant. This differs from the classical
form of X-linked Alport syndrome, caused by mutations in
COL4A5, but it is similar to the autosomal dominant nature of the
probably most common form of Alport syndrome [10]. However,
the incomplete penetrance and high variability at age of diagno-
sis of kidney disease or end-stage renal disease (ESRD) may ob-
scure the real inheritance pattern of the kidney condition. As an
example, Tabibzadeh et al. report one family with members
reaching ESRD at ages ranging from 24 to 78 years [1]. An analysis
of the family incidence of more constant features of the disease,
such as macrothrombocytopenia, may be more informative.
When macrothrombocytopenia is associated to kidney disease,
the diagnosis of MYH9-RD should be suspected in the first place,
and lab reports should be obtained from family members.
WHAT ARE THE KIDNEY FEATURES OF
MYH9-RD?
Tabibzadeh et al. provide an overview of the spectrum of kidney
disease [1]. At Nephrology referral, median age was 30 years
(range 14–76) and estimated glomerular filtration rate 66 mL/
min/1.73 m2, but around 20% were already in ESRD and an addi-
tional 50% progressed to ESRD. While the prior term ‘Alport syn-
drome with macrothrombocytopenia’ and the use of the term
‘nephritis’ in OMIM [7] may evoke the presence of hematuria,
this was only observed at presentation or during follow-up in
around 50% of patients. By contrast, pathological proteinuria
was present in 85% at presentation, may reach nephrotic range
and may even lead to nephrotic syndrome. This fits well with
the expanding phenotypic spectrum of many classical inherited
kidney diseases [11]. While albuminuria was not reported, it
would be expected to be more sensitive than proteinuria. Thus,
the disease should be considered in any proteinuric kidney dis-
ease at any age, especially when accompanied by thrombocyto-
penia. In this regard, one patient had a renal biopsy diagnosis of
focal segmental glomerulosclerosis (FSGS), as previously
reported for MYH9-related nephropathy [1, 12]. The most com-
mon alternative histological diagnosis was mesangial prolifera-
tion without immune deposits [1]. Electron microscopy may
additionally show glomerular basement membrane thickening
and splitting, and focal foot process effacement [1], pathological
findings reminiscent of Alport syndrome, being the main reason
why it was considered the same disease for a long time. The fo-
cal nature of foot process effacement is a finding associated
with secondary FSGS and would argue against treatment with
steroids [13]. Kidney outcomes were very variable, with age at
ESRD ranging from 15 to 78 years, expanding the upper age
range of prior reports [1]. Rapid progression was evident in 4/7
(60%) patients over the age of 40 years, as well as in a 9-year-old
child with normal renal function that reached ESRD 6 years
later, suggesting that the disease may be accelerated by triggers
(Figure 2). Triggers (sepsis and post-partum haemorrhage) were
identified in two patients. This possibility of late onset acceler-
ated progression argues for nephrological assessment and mon-
itoring of all affected family members, independently from
baseline renal function tests.
WHAT OTHER CLINICAL MANIFESTATIONS
MAY BE EXPECTED IN MYH9-RD?
Figure 1 summarizes additional potential clinical manifesta-
tions. Despite the presence of these abnormalities, the diagno-
sis is not easy and may take decades, either because the
abnormalities are missed, the dots are not connected or they
are attributed to other conditions, the most common being idio-
pathic thrombocytopenic purpura (ITP), as clearly illustrated by
Tabibzadeh et al. [1] and Furlano et al. [4]. The combined
FIGURE 1: Clinical spectrum of MYH9-related disease. MATINS:
MAcroThrombocytopenia and granulocyte Inclusions with or without
Nephropathy or Sensorineural hearing loss. Fechtner syndrome: macrothrombocy-
topenia, granulocyte inclusions, nephropathy, sensorineural hearing loss, cata-
racts. Epstein syndrome: macrothrombocytopenia, granulocyte inclusions,
nephropathy, sensorineural hearing loss. Sebastian syndrome and May–Hegglin
anomaly: macrothrombocytopenia and granulocyte inclusions. Granulocyte inclu-
sions visible in May-Grünwald-Giemsa-stained blood smears (Döhle bodies) in the
May–Hegglin anomaly differ ultrastructurally from those in Sebastian syndrome,
but both stain with anti-heavy chain of non-muscle myosin IIA antibodies.
Deafness AD 17: Deafness Autosomal Dominant 17. GI: granulocyte inclusions;
MT: congenital macrothrombocytopenia (more than 40% of platelets are >3.9mM
in diameter); GN: glomerular nephropathy; HL: hearing loss, C: cataracts.
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misdiagnosis of ITP and Alport syndrome has even been
reported [14]. The degree of thrombocytopenia is very variable
(in Tabibzadeh report, platelet numbers ranged from 4000 to
350 000/mL) and thrombocytopenia may be intermittent, i.e.
platelet numbers may be normal. Large-sized platelets may be
missed because they may not be interpreted as platelets by
autoanalysers. The bleeding diathesis is usually mild to moder-
ate, but may lead to significant bleeding, precipitating acute kid-
ney injury, as reported by Tabibzadeh et al. [1]. The high
variability in the severity and penetrance of other manifestations
is also problematic. Hearing loss may be incapacitating, and may
also be late-onset, down-sloping and asymptomatic, and only
uncovered by specific studies [15]. Cataracts may be congenital
[16], develop later in life or never develop. Granulocyte inclusions
will only be found if blood smears are studied. Unexplained ab-
normal liver enzyme levels are not associated with progressive
liver disease but may provide clues for the diagnosis.
The phenotypic spectrum may further expand. There are
isolated reports of acute myeloid leukaemia and myelodysplas-
tic syndrome that may be more difficult to diagnose due to the
abnormal baseline bone marrow [17]. Extramedullary hemato-
poiesis may be confounded for tumours [18]. Defective neutro-
phil migration has been described but the consequences are
poorly understood [19]. Additionally, MYH9 is considered a tu-
mour suppressor, and whether the incidence or severity of ma-
lignancy differs in patients with germline mutations requires
further studies [2]. Congenital haemangioma [20], the MYH9-as-
sociated elastin aggregation (MALTA) syndrome characterized
by sweat duct proliferations and irregular elastin aggregations
[21], and non-syndromic orofacial cleft in Taiwanese patients
[22] have also been associated to MYH9 mutations, but not nec-
essarily with MATINS.
WHEN SHOULD NEPHROLOGISTS SUSPECT
MYH9-RD?
For nephrologists, MYH9-RD should be part of the differential
diagnosis of proteinuric nephropathies at any age, especially if
patients present any of the red flags depicted in Table 1 or a his-
tological diagnosis of FSGS or mesangial proliferation without
immune deposits. FSGS should always be considered a name in
need of a surname: what is the driver of podocyte loss? The di-
agnosis should also always be considered in patients diagnosed
with ITP refered to nephrology.
DO ALL DISEASE-CAUSING MYH9 VARIANTS
CAUSE KIDNEY DISEASE?
The answer appears to be no, although further work is needed
in relation to genotype–phenotype correlations. MYH9 muta-
tions are the most common cause of inherited thrombocytope-
nia, but, as shown in Figure 1, may not be associated with
nephropathy. Motor domain mutations are associated with
more severe kidney disease, but kidney disease may also be ob-
served in tail mutations [2] (Figure 3), and even mutations corre-
sponding to the non-helical tailpiece may be associated with
kidney disease [1].
FIGURE 2: Pathogenic working hypothesis with therapeutic implications: two pathways to MYH9-related ESRD. Hypothesis based on the high heterogeneity of kidney
disease within families with the same mutation, the clinical evidence of rapidly progressive disease at very different age ranges (from childhood to adulthood to the el-
derly) suggestive of the existence of triggers and preclinical evidence supporting the existence of triggers such as angiotensin II hyperactivity, together with evidence
that a diabetic milieu, angiotensin II or other stressors, decrease MYH9 expression. The direct therapeutic implication is that identification and treatment of triggers
may slow disease progression as suggested by certain patients on RAS blockade.
Table 1. Red flags for MYH9-RD in the kidney disease patient
Family history of ITP, bleeding, kidney disease or deafness
ITP AND glomerular nephropathy
Macrothrombocytopenia AND Döhle body-like granulocyte
inclusions
Glomerular nephropathy AND sensorineural deafness AND
cataracts
‘Alport syndrome-like’ AND thrombocytopenia
Steroid-resistant FSGS AND thrombocytopenia
Steroid-resistant FSGS AND deafness
Early onset cataracts
Frequent haematomas
Spontaneous haemorrhages AND/OR excessive bleeding provoked
by haemostatic challenges as trauma or surgery (post-partum,
road accident, anti-platelet agents)
Unexplained liver enzyme abnormalities AND kidney disease
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WHAT IS THE PATHOGENESIS?
The MYH9 gene encodes the heavy chain of non-muscle myosin
IIA, which is involved in cytokinesis, cell adhesion and cytoskel-
eton maintenance [2]. Megakaryocytes are normal but proplate-
let branching is affected and defective megakaryocyte
migration may contribute to ectopic platelet release. Bleeding
may be facilitated by the low number of platelets and by defec-
tive clot formation. Clot contraction drives the translocation of
procoagulant platelets to thrombus surface, but procoagulant
platelets failed to translocate and remained inside the thrombi
in blood derived from MYH9-deficient mice [23]. In the kidney,
podocytes, mesangial cells and tubular cells express non-
muscle myosin IIA. While germline knock-in point mutations
reproducing human genotypes were associated with diverse
manifestations of the disease, including albuminuria and glo-
merulosclerosis [24], not all authors found that podocyte-
specific deficiency was associated to spontaneous glomerular
disease in mice, although increased sensitivity to some podo-
cyte stressors was found, which is consistent with human data
suggestive of potential ‘triggers’ for chronic kidney disease
(CKD) progression (Figure 2) [24–26]. Germline MYH9E1841K/
E1841K mice were more sensitive to diverse triggers: albumin-
uria increased mildly in response to high salt; severe albumin-
uria and FSGS developed in angiotensin II-induced
hypertension; and early mortality followed renal mass reduc-
tion [27]. SLIT2 activation of its receptor ROBO2 may be another
stressor downregulating MYH9 expression and sensitizing to
hypertension-induced podocyte detachment [28]. Both MYH9 mu-
tant and MYH9-deficient cultured podocytes displayed abnormal
podocyte cytoskeletal structure, increased motility and mechani-
cal function [27, 29]. Discrepancies regarding the impact of
podocyte-specific MYH9 deletion in vivo may also point to the con-
tribution of additional cell types. Thus, beyond podocyte injury,
which does take place but may be primary or secondary, defective
glomerular haemodynamics or other factors due to disturbances
in endothelial, mesangial or tubular cell function may also con-
tribute to the pathogenesis, given the human evidence of focal
rather than diffuse foot process effacement. In this regard, MYH9
has also been localized to mesangial, endothelial and proximal,
and distal tubular cells in diverse studies [30, 31].
IS THERE A ROLE FOR MYH9 IN ACQUIRED
KIDNEY DISEASE?
MYH9 expression was decreased in glomeruli from diabetic
patients and animals [32]. Additionally, angiotensin II decreased
MYH9 in cultured podocytes via NOX4-mediated oxidative
stress and TRPC6 activation, and either angiotensin II or MYH9
knockdown resulted in podocyte actin cytoskeleton reorganiza-
tion, reduced cell adhesion and increased albumin permeability
[32]. These findings suggest a role for MYH9 loss in acquired kid-
ney disease and may explain cases of accelerated CKD progres-
sion in patients with MYH9-RD, likely triggered by activation of
the renin-angiotensin system (RAS) or other modulators of
MYH9 expression. In this regard, the MYH9 rs2032487 single nu-
cleotide polymorphism (SNP) (but not APOL1 variants) has been
associated with advanced CKD related to Type 2 diabetes melli-
tus in the Canary Islands, the Spanish region with the highest
prevalence of diabetic kidney disease [33], and the rs3752462
SNP to an increased risk of diabetic kidney disease in Chinese
Han individuals [34], reproducing prior SNP associations in
other non-African populations (reviewed in Pecci et al. [2]).
THE ASSOCIATION THAT WAS NOT
In 2008, MYH9 was described as a major-effect risk gene for FSGS,
underlying an increased risk of ESRD for HIV-associated nephropa-
thy and hypertension-attributed nephropathy in African Americans
[35]. This association was later disproved, and the increased risk is
now known to be conferred by APOL1 gene variants [36].
HOW IS MYH9-RD MANAGED?
Treatment is symptomatic (Figure 4) [2–4]. However, an a etio-
logic diagnosis may be useful in driving therapy, thus avoiding
immune suppression for misdiagnosed ITP and facilitating the
A
B
FIGURE 3: Non-muscle myosin heavy chain IIA structure and sites of mutations. The MYH9 gene encodes the heavy chain of non-muscle myosin IIA. (A) Primary struc-
ture of the heavy chain of non-muscle myosin IIA. Some of the most frequent mutations are indicated. In Italy, 68% of families carried mutations leading to changes in
amino acids 702 (motor domain) or 1424, 1841 and 1933 (tail domain). Motor domain mutations and D1424H are associated with the highest risk of kidney disease [2].
Some mutations are colour-coded in traffic light style as per the risk of kidney disease, red being the highest. (B) Quaternary structure of non-muscle myosin IIA: it is a
hexamer composed two heavy chains, two regulatory light chains, whose phosphorylation regulates protein function, and two essential light chains. Key phosphoryla-
tion sites on the heavy chain are indicated.
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use of thrombopoietin receptor activators to increase platelet
production: both eltrombopag and romiplostim have been suc-
cessfully used, the former in a Phase 3 clinical trial. RAS blockade
has been suggested as therapy for MYH9-related nephropathy
and successful case reports have been published referring to a
decrease in proteinuria associated with stable renal function or
mildly progressive disease [1, 37], but treatment failures have
also been reported [38]. The reason for the heterogenous re-
sponse is unclear. Some genetic variants may be too severe to re-
spond to nephroprotective strategies, while RAS blockade may
protect from triggers, such as RAS activation, which may increase
the severity of the disease by further downregulation of MYH9
expression in some milder genetic variants (Figure 2) [32].
WHAT NEEDS TO BE LEARNT?
Much remains to be learnt about this rare disease. From the kid-
ney point of view, what are the factors driving the heterogeneity
in kidney outcomes even within the same family? Could exome
studies provide clues to the highly variable penetrance of kid-
ney disease? Do relatively frequent genetic variants in
nephropathy-associated genes (Type IV collagen genes?) con-
tribute to increase severity? What are the triggers for acceler-
ated loss of kidney function? Could these triggers be treatable?
When should RAS blockade be started in affected family mem-
bers? What are cost-effective methods to screen for the disease,
given the underdiagnosis, late diagnoses and evidence that it is
frequently treated with ineffective and potentially dangerous
approaches due to misdiagnosis? In this regard, recent charac-
terization of subclinical red blood cell abnormalities as well as
an improved understanding of the flow cytometry characteris-
tics of platelets may one day allow screening for the disease in
routine blood cell studies. Abnormalities that could be useful in
screening for MYH9-RD are the presence of elongated red blood
cells, immunostaining for granulocyte inclusions, assessment
of mean platelet diameter, or further standardization of mean
platelet volume assessments or cut-off points [39–42]. Patients
thus identified should be monitored for early features of kidney
involvement (albuminuria). Increased awareness among
nephrologists together with the widespread use of massive par-
allel sequencing will allow the diagnosis of MYH9-RD in
patients presenting with a wide range of phenotypes mostly far
from the full-blown syndrome.
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